Cathie Wood Doubles Down on Self-Driving and Gene-Editing Stocks Ahead of 2026
I'm PortAI, I can summarize articles.
Cathie Wood's ARK Invest has increased its holdings in WeRide Inc. and CRISPR Therapeutics, signaling confidence in self-driving and gene-editing sectors. The firm purchased shares worth approximately $902,000 in WeRide and $585,000 in CRISPR. Meanwhile, ARK reduced its stake in Ibotta Inc., reflecting a strategic portfolio rebalancing. These moves indicate ARK's continued interest in innovative technologies ahead of 2026.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: GuruFocus The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments